Fig. 1From: Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinomaChanges of tumor lesions in sequential PET-CT examinations in the period of CART-EGFR cell infusion. a PET-CT examination illustrated hepatic hilar malignancy before surgery. b PET-CT examined after the completion of radiotherapy with illustration of a new metastatic hypermetabolic lesion in the hepatic caudate lobe and enlarged soft tissue and retroperitoneal lymph node metastases. c PET-CT assessment 6Â weeks after the infusion of CART-EGFR cells showed a more than 80% shrinkage of metastatic lesions in the hepatic hilar region and caudate lobe. d Routine examination by PET-CT showed a persistent PR status 4Â months after the CART-EGFR cell infusion. e PET-CT detected multiple new SUV abnormal lesions in the omentum majus, peritoneum, and abdominal cavity 8.5Â months after the first cycle of CART-EGFR cell infusion. f The examination of PET-CT detected newly emerged metastases in the bottom of the pelvis, right liver lobe, and left supraclavicular lymph node as well as enlargement of previous tumor lesions in the abdomen 4Â weeks after the combination of anti-PD-1 antibody and CART-EGFRBack to article page